← Leaderboards
Dineo Khabele
Washington University
$4,937,606
Attributed
$6,383,857
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $870.9K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,383,857 · 10
By mechanism
R01$4,373,478 · 2
K08$795,420 · 1
G12$460,661 · 4
R21$384,098 · 1
K12$340,200 · 1
R13$30,000 · 1
Top collaborators
- Todd D Giorgio6 shared
- Fiona E Yull6 shared
- Sarah K. England1 shared
Most similar at Washington University
Same institution · by research overlap
- Kelle H Moley$25,167,882
- Celia M Santi$7,398,391
- Michelle Catherine Sabo$2,398,652
- David B Wilson$1,563,823
- Irving Nmn Boime$1,885,223
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryPublishingIn VivoTumorDesignInsightPre-ClinicalPharmaceutical PreparationsChemotherapyIn VitroPre-Clinical ModelInhibitor/AntagonistClinical TrialsPhenotypeResistanceRegimenCancer CellHistone Deacetylase InhibitorBaseClinically RelevantGenetic TranscriptionToxic EffectAntitumor EffectCancer Model
Grant awards (30)
WashU-WRHR; Gateway to Improving Women's Reproductive Health$340,200
K12 · FY2025 · HD · contact PI
SRI Meeting: Training and Development in the Reproductive Sciences$10,000
R13 · FY2025 · HD · contact PI
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer$412,827
R01 · FY2024 · CA · contact PI
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer$105,398
R01 · FY2024 · CA · contact PI
SRI Meeting: Training and Development in the Reproductive Sciences$10,000
R13 · FY2024 · HD · contact PI
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer$446,118
R01 · FY2023 · CA · contact PI
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer$109,193
R01 · FY2023 · CA · contact PI
SRI Meeting: Training and Development in the Reproductive Sciences$10,000
R13 · FY2023 · HD · contact PI
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer$423,986
R01 · FY2022 · CA · contact PI
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer - Diversity Supplement$69,487
R01 · FY2022 · CA · contact PI
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer$446,882
R01 · FY2021 · CA · contact PI
Macrophage-based ovarian cancer immunotherapy$424,055
R01 · FY2021 · CA
Macrophage-based ovarian cancer immunotherapy$358,694
R01 · FY2020 · CA
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer$322,610
R01 · FY2020 · CA · contact PI
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer$122,750
R01 · FY2020 · CA · contact PI
Macrophage-based ovarian cancer immunotherapy$53,152
R01 · FY2020 · CA
Macrophage-based ovarian cancer immunotherapy$347,926
R01 · FY2019 · CA
Macrophage-based ovarian cancer immunotherapy$358,683
R01 · FY2018 · CA
Targeting Cyclin E in Ovarian Cancer with Histone Deacetylase Inhibitors$202,078
R21 · FY2018 · CA · contact PI
Macrophage-based ovarian cancer immunotherapy$371,717
R01 · FY2017 · CA
Targeting Cyclin E in Ovarian Cancer with Histone Deacetylase Inhibitors$182,020
R21 · FY2017 · CA · contact PI
Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian Cancer$159,084
K08 · FY2014 · CA · contact PI
Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian Cancer$159,084
K08 · FY2013 · CA · contact PI
Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian Cancer$159,084
K08 · FY2012 · CA · contact PI
Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian Cancer$159,084
K08 · FY2011 · CA · contact PI
Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian Cancer$159,084
K08 · FY2010 · CA · contact PI
DISSECTING COX-1 RELATED GENE PATHWAYS IN OVARIAN CANCER$72,316
G12 · FY2009 · RR · contact PI
DISSECTING COX-1 RELATED GENE PATHWAYS IN OVARIAN CANCER$140,014
G12 · FY2008 · RR · contact PI
DISSECTING COX-1 RELATED GENE PATHWAYS IN OVARIAN CANCER$144,965
G12 · FY2007 · RR · contact PI
DISSECTING COX-1 RELATED GENE PATHWAYS IN OVARIAN CANCER$103,366
G12 · FY2006 · RR · contact PI